Allist(688578)2023-09-25 02:10Financial Performance - The company achieved total revenue of CNY 749 million in the first half of 2023, representing a year-on-year increase of 149.24% [4] - Net profit attributable to the parent company reached CNY 208 million, a growth of 678.69% compared to the previous year [4] - The net profit attributable to the parent company after deducting non-recurring gains and losses was CNY 184 million, up 3,976.33% year-on-year [4] Market Coverage - The company's marketing team has covered over 1,000 hospitals across more than 30 provinces and cities [5] - The commercial partner, Jiangsu Fuxing Pharmaceutical Co., Ltd., has reached over 2,000 hospitals [5] Product Development and Research - The company invested CNY 132 million in R&D in the first half of 2023, with CNY 113 million being expensed and CNY 19.06 million capitalized [8] - As of June 30, 2023, the R&D team comprised 167 members, including 68 with master's degrees and 18 with doctoral degrees [8] Clinical Trials and Efficacy - The FAVOUR study showed an objective response rate (ORR) of 78.6% for the initial treatment group at 240 mg, with a median duration of response (DoR) of 15.2 months [6] - The safety profile of the drug was favorable, with most treatment-related adverse events (TRAEs) being grade 1-2 [7] Regulatory and Market Strategy - The drug was included in the national medical insurance reimbursement list as of March 1, 2023, which is expected to support sales performance for the year [4] - The company plans to continue expanding its R&D investments and product pipeline, focusing on new indications for the drug [8] Competitive Advantages - The drug is recognized for its differentiated competitive advantages, including high efficacy, safety, and a wide therapeutic window [12] - The company is actively pursuing business development opportunities, particularly in the lung cancer field, to enhance its product offerings [11]